<DOC>
	<DOCNO>NCT02652260</DOCNO>
	<brief_summary>This study aim evaluate switch fix dose combination ( FDC ) treatment ATRIPLA^TM 12 week prior screen FDC treatment MK-1439A virologically-suppressed , human immunodeficiency virus type 1 ( HIV-1 ) -infected participant . The primary hypothesis switch ATRIPLA^TM MK-1439A result low proportion participant least one CNS toxicity least Grade 2 intensity Week 12 continuation ATRIPLA^TM treatment .</brief_summary>
	<brief_title>Effects Switching From ATRIPLA^TM ( Efavirenz , Tenofovir , Emtricitabine ) MK-1439A ( Doravirine , Tenofovir , Lamivudine ) Virologically-Suppressed Participants ( MK-1439A-028 )</brief_title>
	<detailed_description />
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>take ATRIPLA^TM , generic version ATRIPLA^TM , component ATRIPLATM ( EFV , TDF plus emtricitabine ) , documentation HIV1 ribonucleic acid ( RNA ) &lt; 50 copies/mL 12 week prior screen ATRIPLA^TM . plasma HIV1 RNA level limit quantification ( BLoQ ) screen visit . genotyped prior start initial antiretroviral regimen , must know resistance study agent least one EFVassociated CNS toxicity Grade 2 bad intensity time screen Study Day 1 highly unlikely become pregnant impregnate partner user recreational illicit drug recent history drug alcohol abuse dependence . ongoing Grade 4 CNS toxicity screen period require prompt change ART treat viral infection HIV1 , hepatitis B , agent active HIV1 include , limited , adefovir , emtricitabine , entecavir , lamivudine tenofovir . document known resistance study drug include MK1439 , lamivudine , and/or tenofovir participate , anticipate participate study investigational compound/device within 30 day prior sign inform consent use systemic immunosuppressive therapy immune modulators anticipate use within 30 day prior study require anticipates require prohibit medication significant hypersensitivity contraindication component study drug current ( active ) diagnosis acute hepatitis due cause . evidence decompensated liver disease manifest presence history ascites , esophageal gastric variceal bleeding , hepatic encephalopathy sign symptom advance liver disease , liver cirrhosis ChildPugh Class C score PughTurcotte ( CPT ) score &gt; 9. pregnant , breastfeeding , expect conceive . female expect donate egg ( time study ) male expect donate sperm ( time study ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>